1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

US FDA's Slim October User Fee Calendar Brings Some Controversy

 
• By Bridget Silverman

Advisory committee concerns cast clouds over Iterum’s oral antibiotic, Intercept’s Ocaliva, and perioperative immuno-oncology regimens, while CSL and Pfizer aim to take their hematology franchises in new directions.

October calendar
Fewer FDA approvals are expected in October compared to the prior month, based on the number of user fee goals. • Source: Shutterstock

October will see a slowdown in US Food and Drug Administration approval activity, with fewer than half as many user fee goal dates as September.

Key Takeaways

  • The US FDA is scheduled to decide the future of Intercept’s Ocaliva and Iterum’s oral sulopenem after negative advisory committee reviews.

The regulatory shoe is set to drop on two applications that endured rough advisory committee reviews, according to the Pink...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers